financial statements
The full income statement, balance sheet, and cash-flow statement for Regeneron Pharmaceuticals Inc. (REGN), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 14.3B YoY+1.0% | 14.2B YoY+8.3% | 13.1B YoY+7.8% | 12.2B YoY-24.3% | 16.1B YoY+89.1% | |
| Research & development | 5.85B YoY+14.0% | 5.13B YoY+15.6% | 4.44B YoY+23.6% | 3.59B YoY+25.6% | 2.86B YoY+8.1% | |
| Selling, general & administrative | 2.70B YoY-8.6% | 2.95B YoY+12.3% | 2.63B YoY+24.4% | 2.12B YoY+15.9% | 1.82B YoY+35.6% | |
| Amortization of intangibles | 179M YoY+38.7% | 129M YoY+39.8% | 92.2M YoY+145.2% | 37.6M | 0.00 | |
| Provision for credit losses | — | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating income | 3.58B YoY-10.3% | 3.99B YoY-1.4% | 4.05B YoY-14.6% | 4.74B YoY-47.0% | 8.95B YoY+150.1% | |
| Interest expense | 43.8M YoY-20.7% | 55.2M YoY-24.4% | 73.0M YoY+22.9% | 59.4M YoY+3.7% | 57.3M YoY+0.7% | |
| Other non-operating income | 1.70B YoY+100.9% | 844M YoY+275.0% | 225M YoY+25.6% | 179M YoY-58.9% | 436M YoY+50.1% | |
| Pre-tax income | 5.23B YoY+9.4% | 4.78B YoY+13.8% | 4.20B YoY-13.6% | 4.86B YoY-47.9% | 9.33B YoY+144.7% | |
| Income tax | 726M YoY+97.6% | 367M YoY+49.5% | 246M YoY-52.8% | 520M YoY-58.4% | 1.25B YoY+320.8% | |
| Net income | 4.50B YoY+2.1% | 4.41B YoY+11.6% | 3.95B YoY-8.9% | 4.34B YoY-46.3% | 8.08B YoY+129.9% | |
$41.48 YoY+8.2% | $38.34 YoY+10.3% | $34.77 YoY-9.0% | $38.22 YoY-46.9% | $71.97 YoY+135.8% | ||
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
18.0B YoY-3.4% | 18.7B YoY-4.2% | 19.5B YoY+22.6% | 15.9B YoY+13.3% | 14.0B YoY+43.3% | ||
40.6B YoY+7.4% | 37.8B YoY+14.1% | 33.1B YoY+13.2% | 29.2B YoY+14.9% | 25.4B YoY+48.2% | ||
4.37B YoY+10.8% | 3.94B YoY+15.2% | 3.42B YoY+9.0% | 3.14B YoY-20.1% | 3.93B YoY+45.8% | ||
9.30B YoY+10.7% | 8.41B YoY+18.3% | 7.11B YoY+8.5% | 6.55B YoY-1.7% | 6.67B YoY+8.6% | ||
31.3B YoY+6.5% | 29.4B YoY+13.0% | 26.0B YoY+14.6% | 22.7B YoY+20.8% | 18.8B YoY+70.2% | ||
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
4.98B YoY+12.6% | 4.42B YoY-3.8% | 4.59B YoY-8.4% | 5.01B YoY-29.2% | 7.08B YoY+170.5% | ||
-629M YoY+74.5% | -2.47B YoY+22.5% | -3.19B YoY+15.8% | -3.78B YoY+29.7% | -5.38B YoY-7527.1% | ||
-3.72B YoY-68.8% | -2.20B YoY-22.9% | -1.79B YoY-77.4% | -1.01B YoY-0.3% | -1.01B YoY+49.0% | ||
| FX effect on cash | 300K YoY+142.9% | -700K YoY-75.0% | -400K | 0.00 | 0.00 | |
| Net change in cash | 635M YoY+355.1% | -249M YoY+34.8% | -382M YoY-272.4% | 221M YoY-68.0% | 691M YoY+19.7% | |
| Interest paid | 41.6M YoY-20.9% | 52.6M YoY-28.0% | 73.1M YoY+36.1% | 53.7M YoY-3.8% | 55.8M YoY+140.5% | |
| Income taxes paid | 1.25B YoY+68.6% | 743M YoY-14.6% | 870M YoY-42.1% | 1.50B YoY+23.3% | 1.22B YoY+547.7% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 72.5B YoY+8.4% | 66.9B YoY-18.9% | 82.5B YoY+21.7% | 67.8B YoY+14.2% | 59.3B YoY+30.7% | |
| P/E | 16.1× YoY+6.1% | 15.2× YoY-26.6% | 20.7× YoY+63.8% | 12.6× YoY+71.8% | 7.3× YoY-43.1% | |
| P/S | 5.1× YoY+7.3% | 4.7× YoY-25.2% | 6.3× YoY+27.4% | 4.9× YoY+33.9% | 3.7× YoY-30.9% | |
| P/B | 2.3× YoY+1.8% | 2.3× YoY-31.2% | 3.3× YoY+4.8% | 3.2× YoY+0.0% | 3.2× YoY-23.2% | |
| P/FCF | 17.8× YoY-2.7% | 18.3× YoY+1.9% | 17.9× YoY+34.2% | 13.4× YoY+47.0% | 9.1× YoY-59.9% | |
| Earnings yield | 6.2% YoY-5.8% | 6.6% YoY+36.3% | 4.8% YoY-38.9% | 7.9% YoY-41.8% | 13.6% YoY+75.8% | |
| FCF yield | 5.6% YoY+2.8% | 5.5% YoY-1.9% | 5.6% YoY-25.5% | 7.5% YoY-32.0% | 11.0% YoY+149.3% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: REGN's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all REGN filings on SEC EDGAR → Not investment advice.